# Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer

> **NCT06129422** · PHASE1 · COMPLETED · sponsor: **Nihon Medi-Physics Co., Ltd.** · enrollment: 10 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** NMK89

## Key facts

- **NCT ID:** NCT06129422
- **Lead sponsor:** Nihon Medi-Physics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-31
- **Primary completion:** 2025-10-07
- **Final completion:** 2025-10-07
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06129422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06129422, "Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06129422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*